ImmuCell (NASDAQ:ICCC) Issues Quarterly Earnings Results

ImmuCell (NASDAQ:ICCC) announced its quarterly earnings data on Tuesday. The biotechnology company reported $0.06 earnings per share for the quarter, Zacks reports. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%.

ImmuCell Trading Up 1.6 %

Shares of ImmuCell stock traded up $0.08 on Tuesday, hitting $5.10. 2,267 shares of the company traded hands, compared to its average volume of 5,716. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The company has a market cap of $45.45 million, a PE ratio of -10.20 and a beta of 0.54. The stock’s 50 day moving average price is $5.11 and its 200-day moving average price is $4.26. ImmuCell has a 52 week low of $3.34 and a 52 week high of $5.82.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.